|
[1]
|
Baranowska-Kortylewicz J, Dalrymple GV, Harrison KA, et al. On the safety 5-[125I]iodo-2-deoxy-uridine preclinical evaluation in swine[J]. Acta Oncol, 1996, 35(7):925-933. |
|
[2]
|
Taverna P, Hwang HS, Schupp JE, et al. Inhibition of base excision repair potentiates iododeoxyuridine-induced eytotoxicity and radiosensitization[J]. Cancer Res, 2003, 63(4):838-846. |
|
[3]
|
Yan T, Seo Y, Schupp JE, et al. Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence. Mol Cancer Ther, 2006, 5(4):893-902. |
|
[4]
|
Dupertuis YM, Xiao WH, De Tribolet N, et al. Unlabeled iododeoxyuridine increase the rate of uptake of[125] iododeoxyuridine in human xenografted glioblastomas[J]. Eur J Nucl Med Mol Imaging, 2002, 29(4):499-505. |
|
[5]
|
Howell RW, Bishayee A. Bystander effects caused by nonuniform distributions of DNA-incorporated(125)I[J]. Micron, 2002, 33(2):127-132. |
|
[6]
|
Xue LY, Butler NJ, Makrigiorgos GM, et al. Bystander effect produced by radiolabeled tumor cells in vivo[J]. Proc Nat Acad Sci USA, 2002, 99(21):13765-13770. |
|
[7]
|
Kassis AI, Wen PY, Van den Abbeele AD, et al. 5-[125I]iodo-2-deoxyuridine in the of brain radiotherapy tumors in rats[J]. J Nucl Med, 1998, 39(7):1148-1154. |
|
[8]
|
Kassis AI, Dahman BA, Adalstein SJ. In vivo therapy of neoplastic meningitis with methotrexate and 5-[125I]iodo-2-deoxyuridine[J]. Acta Oncol, 2000, 39(6):731-737. |
|
[9]
|
Galanis E, Goldberg R, Reid J, et al. Phase Ⅰ trial of sequential administration of raltitrexed(Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd)[J]. Ann Oncol, 2001, 12(5):701-707. |
|
[10]
|
Dupertuis YM, Vazquez M, Mach JP, et al. Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine[J]. Cancer Res, 2001, 61(21):7971-7977. |
|
[11]
|
Seo Y, Yan T, Schupp JE, et al. The interaction between two radiosensitizers:5-iododeoxyuridine and caffeine[J]. Cancer Res, 2006, 66(1):490-498. |
|
[12]
|
马晓东,Dillehay LE,Williams JR,et al.局部缓释125I-UdR治疗恶性星形细胞瘤实验研究[J].中华神经外科疾病研究杂志,2005,4(4):293-298.
|
|
[13]
|
Malrs RJ, Wideman CL, Angerson WJ, et al. Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model[J]. Br J Cancer, 2000, 82(1):74-80. |
|
[14]
|
Kinsella TJ, Vielhuber KA, Kunugi KA, et al. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyufidine radiosensitization in U251 human glioblastoma xenografts[J]. Clin Cancer Res, 2000, 6(4):1468-1475. |
|
[15]
|
Harrington K J, Syrigos KN, Uster PS, et al. Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xneograft model[J]. Br J Cancer, 2004, 91(2):366-373. |
|
[16]
|
Semnani ES, Wang K, Adelstein SJ, et al. 5-[123I/125I]iodo-2-deoxyuridine in metastatic lung cancer:radiopharmaceutical formulation affects targeting[J]. J Nucl Med, 2005, 46(5):800-806. |
|
[17]
|
Chiou RK, Dalrymple GV, Baranowska-Kortylewicz J, et al. Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer[J]. J Urology, 1999, 162(1):58-62. |
|
[18]
|
Macapinlac HA, Kemeny N, Daghighian F, et al. Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver[J]. J Nucl Med, 1996, 37(4 suppl):25s-29s. |
|
[19]
|
Ou XH, Kuang AR, Peng X, et al. Study on the possibility of insulin as a carrier of IUdR for hepatocellular carcinoma-targeted therapy[J]. World J Gastroenterol, 2003, 9(8):1675-1678. |
点击查看大图
下载: